Hepatic arterial infusion chemotherapy for unresectable confined liver metastases: prediction of systemic toxicity with the application of a scintigraphic and pharmacokinetic approach

被引:0
作者
Ettore Pelosi
Fabrizio Bar
Stefania Battista
Marilena Bellò
Maria Cesira Bucchi
Oscar Alabiso
Gianpaolo Molino
Gianni Bisi
机构
[1] Department of Nuclear Medicine,
[2] University of Turin,undefined
[3] Corso Dogliotti 14,undefined
[4] I-10126 Turin,undefined
[5] Italy Tel.: +39-011-6964390; Fax: +39-011-6634751,undefined
[6] Division of General Medicine A,undefined
[7] San Giovanni Battista Hospital,undefined
[8] Corso Bramante 88,undefined
[9] I-10126 Turin,undefined
[10] Italy,undefined
[11] Division of Esophageal and Oncological Surgery,undefined
[12] University of Turin,undefined
[13] Corso Dogliotti 14,undefined
[14] I-10126 Turin,undefined
[15] Italy,undefined
来源
Cancer Chemotherapy and Pharmacology | 1999年 / 44卷
关键词
Key words Perfusion imaging; Regional chemotherapy; Secondary liver neoplasms; Sorbitol; Systemic toxicity;
D O I
暂无
中图分类号
学科分类号
摘要
Purpose: The incorrect positioning of the arterial Port-a-Cath or the presence of anatomic or functional hepatic arteriovenous shunting may explain the occurrence of systemic toxicity of hepatic arterial infusion of floxuridine in patients with liver metastases. The aim of our study was to predict the occurrence of systemic toxic effects from this treatment using a scintigraphic and pharmacokinetic approach. Methods: A group of 26 patients were studied. Before treatment, Tc-99m-labelled macroaggregated albumin arterial perfusion scintigraphy was performed to verify the correct positioning of the catheter, to evaluate the percentage of pulmonary uptake of the tracer, reflecting intrahepatic arteriovenous anatomic shunting, and to qualitatively assess the perfusion pattern of the metastases with respect to the normal liver parenchyma (SPECT images). Hepatic arteriovenous functional shunting was assessed through the bioavailability of intraarterially administered D-sorbitol. Treatment was then started and systemic toxic effects were evaluated according to WHO recommendations. Results: No correlation was found between anatomic shunting (≤10% in all patients) and systemic toxicity of treatment. The 9 patients with hypoperfused metastases experienced a significantly lower level of toxic effects (1 low-grade toxicity and 8 no toxicity) than the 17 with hyperperfused metastases (6 high-grade toxicity, 5 low-grade and 6 no toxicity; χ2 = 7.170, P = 0.028). Functional shunting was significantly different in patients with high-grade, low-grade and no toxicity (46.5 ± 19.9%, 15.8 ± 12.7% and 16.5 ± 10.3%, respectively; P<0.001 by analysis of variance). Moreover, functional shunting was significantly greater only in patients with hyperperfused metastases who developed high-grade toxicity. Conclusions: A protocol combining scintigraphic and pharmacokinetic methods is of value in the individual patient in assessing the risk of high-grade systemic toxicity during hepatic arterial infusion of floxuridine. A flow-chart used in our ongoing prospective study for the evaluation of patients undergoing regional chemotherapy for liver metastases is included.
引用
收藏
页码:505 / 510
页数:5
相关论文
empty
未找到相关数据